Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CR 1
Formulation 1 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Formulation 1 | EXPERIMENTAL | - |
| Formulation 2 | EXPERIMENTAL | - |
| Formulation 3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Formulation 1 | DRUG | 150-mg immediate release tablet (single dose) |
| Formulation 2 | DRUG | 150-mg modified release capsule, short duration (single dose) |
| Formulation 3 | DRUG | 150-mg modified release capsule, long duration (single dose) |
Inclusion Criteria: * Healthy male and/or female (non-childbearing potential) subjects between the ages of 21 and 55 years, inclusive. * Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs). * An informed consent document signed and dated by the subject. Exclusion...
Top 20 of 31 competitors
Formulation 1 is an investigational small molecule developed by Pfizer, Inc. (ticker: PFE). It is being studied for rheumatoid arthritis and has completed a Phase 1 clinical trial. It is also known by the alternative names CR 1 and 1.
Formulation 1 is being developed for the treatment of rheumatoid arthritis. It is an investigational therapy and has not been approved for any indication. Its only completed clinical trial to date enrolled healthy volunteers, not patients with rheumatoid arthritis.
Formulation 1 is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker symbol PFE. Pfizer is the sponsor of the clinical program for this investigational small molecule.
Formulation 1 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The completed study enrolled 12 healthy volunteers in Singapore.
Formulation 1 has been evaluated in one completed Phase 1 trial, NCT01351129, titled "Single Dose Study To Compare Pharmacokinietics Of 3 Different Formulations Of PF-04991532 In Healthy Volunteers." The trial enrolled 12 healthy volunteers in Singapore and was controlled and randomized but not double-blind.
Yes, Formulation 1 is also known as CR 1 and 1. These alternative names refer to the same investigational small molecule developed by Pfizer, Inc. for rheumatoid arthritis.